MedTrace Logo

Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With House Dust Mites

NCT03963947 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 97

Last updated 2023-05-25

No results posted yet for this study

Summary

Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltavac® Polymerised With House Dust Mite in pediatric allergic patients

Conditions

  • Rhinoconjunctivitis With or Without Allergic Asthma

Interventions

BIOLOGICAL

Beltavac® Polymerized with house dust mites

Adminstration of Beltavac® Polymerized with house dust mites according to the routine clinical practice

Sponsors & Collaborators

  • Probelte Pharma S.L.U.

    collaborator INDUSTRY

  • Alfons Malet i Casajuana

    lead OTHER

Eligibility

Min Age
3 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2023-05-24
Completion
2023-05-24

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03963947 on ClinicalTrials.gov